Localized Pharmacological Treatment of Ocular Tissue Using High-Intensity Pulsed Electrical Fields

• US 20110144562A1
• Filed: 12/14/2009
• Published: 06/16/2011
• Est. Priority Date: 12/14/2009
• Status: Abandoned Application

• Current Assignee: Alcon Research Limited (Nestle SA)
• Original Assignee: Alcon Research Limited (Nestle SA)
• Inventors: Huculak, John C., Kovalcheck, Steven W., Heeren, Tammo
• Application Number:
  US12/637,302
• Publication Number:
  US 20110144562A1
• Time in Patent Office: Days
• US Class Current: 604/20
• CPC Class Codes: A61F 9/0008 Introducing ophthalmic products into the ocular cavity or retaining products therein putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00
• CPC Class Codes: A61F 9/007 Methods or devices for eye surgery
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

A high-intensity pulsed-electrical-field (HIPEF) apparatus treats ocular tissue within a localized portion of an eye with a pharmacological solution. To mitigate risk of damage to adjacent, healthy ocular tissue, the apparatus delivers the solution to only a portion of the eye and then alters the effectiveness of at least some of the solution delivered by applying a HIPEF. In some embodiments, for example, the apparatus delivers an inactive pharmacological solution and then activates at least some of the solution by applying a HIPEF to that solution. As the apparatus applies the HIPEF with high precision, the HIPEF only activates solution within select portions of the eye. In other embodiments, the apparatus delivers a pharmacological carrier encapsulating an active pharmacological solution and then penetrates the carrier by applying a HIPEF. Delivered with a high concentration, but low dose, the solution diffuses only to tissue within a localized portion of the eye.

Claims

1. A method for treating ocular tissue within a localized portion of an eye during eye surgery with a pharmacological solution, the method comprising:

delivering a pharmacological solution to ocular tissue within a portion of an eye; and

altering the effectiveness of at least some of the pharmacological solution on treatment of ocular tissue within said portion by applying a high-intensity pulsed electrical field to said at least some solution, using a high-intensity pulsed-electrical-field (HIPEF) probe.

2. The method of claim 1, wherein delivering a pharmacological solution to ocular tissue within a portion of the eye comprises delivering a pharmacological carrier encapsulating an active pharmacological solution to said ocular tissue.

3. The method of claim 2, wherein altering the effectiveness of at least some of the pharmacological solution on treatment of ocular tissue within said portion by applying a high-intensity pulsed electrical field to said at least some solution comprises penetrating the pharmacological carrier, and thereby exposing the ocular tissue to the active pharmacological solution, by applying the high-intensity pulsed electrical field to said pharmacological carrier.

4. The method of claim 2, wherein delivering a pharmacological carrier encapsulating an active pharmacological solution comprises delivering a liposome carrier encapsulating the active pharmacological solution.

5. The method of claim 1, wherein delivering a pharmacological solution to ocular tissue within a portion of the eye comprises delivering an inactive pharmacological solution to said ocular tissue.

6. The method of claim 1, wherein altering the effectiveness of at least some of the pharmacological solution on treatment of ocular tissue within said portion by applying a high-intensity pulsed electrical field to said at least some solution comprises activating at least some of said inactive pharmacological solution by applying the high-intensity pulsed electrical field to said at least some inactive pharmacological solution.

7. The method of claim 1, wherein delivering a pharmacological solution to ocular tissue within a portion of an eye comprises delivering a highly concentrated pharmacological solution to said ocular tissue, in a low dose.

8. The method of claim 1, wherein delivering a pharmacological solution to ocular tissue within a portion of an eye comprises delivering the pharmacological solution to retinal tissue within a portion of the eye.

9. The method of claim 1, further comprising dissociating and removing vitreous tissue adjacent said ocular tissue with said HIPEF probe, and, responsive thereto, delivering the pharmacological solution to said ocular tissue and altering the effectiveness of at least some of the pharmacological solution.

10. A high-intensity pulsed-electrical-field (HIPEF) apparatus for treating ocular tissue within a localized portion of an eye during eye surgery with a pharmacological solution, the HIPEF apparatus comprising:

an irrigation system configured to deliver a pharmacological solution to ocular tissue within a portion of an eye; and

a HIPEF probe configured to alter the effectiveness of at least some of the pharmacological solution on treatment of ocular tissue within said portion by applying a high-intensity pulsed electrical field to said at least some solution.

11. The HIPEF apparatus of claim 10, wherein the irrigation system is configured to deliver a pharmacological solution to ocular tissue within a portion of the eye by delivering a pharmacological carrier encapsulating an active pharmacological solution to said ocular tissue.

12. The HIPEF apparatus of claim 11, wherein the HIPEF probe is configured to alter the effectiveness of at least some of the pharmacological solution on treatment of ocular tissue within said portion by penetrating the pharmacological carrier, and thereby exposing the ocular tissue to the active pharmacological solution, by applying the high-intensity pulsed electrical field to said pharmacological carrier.

13. The HIPEF apparatus of claim 11, wherein the HIPEF probe is configured to deliver a liposome carrier encapsulating the active pharmacological solution.

14. The HIPEF apparatus of claim 10, wherein the irrigation system is configured to deliver a pharmacological solution to ocular tissue within a portion of the eye by delivering an inactive pharmacological solution to said ocular tissue.

15. The HIPEF apparatus of claim 14, wherein the HIPEF probe is configured to alter the effectiveness of at least some of the pharmacological solution on treatment of ocular tissue within said portion by activating at least some of said inactive pharmacological solution, by applying the high-intensity pulsed electrical field to said at least some inactive pharmacological solution.

16. The HIPEF apparatus of claim 10, wherein the irrigation system is configured to deliver a pharmacological solution to ocular tissue within a portion of the eye by delivering a highly concentrated pharmacological solution to said ocular tissue, in a low dose.

17. The HIPEF apparatus of claim 10, wherein the irrigation system is configured to deliver a pharmacological solution to retinal tissue within a portion of the eye.

18. The HIPEF apparatus of claim 10, wherein the HIPEF apparatus is further configured to dissociate and remove vitreous tissue adjacent said ocular tissue, and wherein the irrigation system and HIPEF probe are configured to deliver the pharmacological solution to said ocular tissue and alter the effectiveness of at least some of the pharmacological solution responsive to said dissociation and removal of vitreous tissue.